PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsNew drug stops cancer cells from repairing their DNA

BioNews

New drug stops cancer cells from repairing their DNA

Published 26 June 2020 posted in News and appears in BioNews 1053

Author

Joanne Delange

Genetics Editor
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A new drug targeting a cancer's ability to repair its DNA has shown favourable results in its first clinical trial...

A new drug targeting a cancer's ability to repair its DNA has shown favourable results in its first clinical trial.

The phase I trial was designed to test the drug's safety, yet results have shown that in half of the patients given the new drug, berzosertib, their cancer stopped growing, and in two patients their tumour shrunk or completely disappeared.

Lead author Professor Johann de Bono, head of drug development at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust, London, said: 'Our new clinical trial is the first to test the safety of a brand new family of targeted cancer drugs in people, and it's encouraging to see some clinical responses even at this early stage.'

Berzosertib belongs to a new class of drugs known as ATR inhibitors, which work by blocking an important protein that helps cancer cells repair DNA damage. By blocking this protein, cancer cells can be killed by preventing them from being able to repair their DNA.

Scientists at the ICR and the Royal Marsden published the results of their clinical trial in the Journal of Clinical Oncology. In the phase I trial, the scientists gave berzosertib, either on its own or with chemotherapy, to 40 patients with very advanced tumours.

The dose at which the drug is safe for use in further clinical trials was established, and the scientists also discovered that berzosertib only caused mild side-effects. Surprisingly for a phase I trial, the scientists found the drug stopped tumours growing in over half of the patients who were given the drug, either on its own, or with chemotherapy.

Professor Paul Workman, chief executive of the ICR, said: 'Targeting a cancer's ability to repair its DNA is a fundamentally important avenue of cancer research... It's exciting to see the first clinical trial of a drug targeting a key player in the DNA repair process have such promising results, and I look forward to the results of further studies testing the benefit of this new family of targeted treatments.'

The drug's beneficial effect was even more clear in patients who also received chemotherapy, with 71 percent of patients seeing their cancer stabilise.

A patient with advanced bowel cancer was administered berzosertib on its own. His tumours disappeared and he has remained cancer-free for over two years.

A further patient with advanced ovarian cancer was administered berzosertib and chemotherapy. This combination therapy resulted in her tumours shrinking, even after her cancer had returned after becoming resistant to her original drug treatment.

Berzosertib is now moving forward in clinical development and it is hoped can be developed into a new targeted drug treatment for very advanced cancer patients.

Professor de Bono concluded: 'In future, this new class of ATR inhibiting drugs could boost the effect of treatments like chemotherapy that target cancer DNA, expand our range of treatment options and overcome resistance to other targeted treatments.'

Sources and References

  • 22/06/2020
    Institute of Cancer Research
    New class of precision medicine strips cancer of its DNA defences
  • 22/06/2020
    Evening Express
    'Encouraging' results in drug trial that stops cancer cells from repairing DNA
  • 22/06/2020
    Journal of Clinical Oncology
    Phase I trial of First-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors

Related Articles

PET BioNews
News
28 January 2021 • 2 minutes read

Complete sequence of DNA repair mechanism identified

by Lopamudra Banerjee

The entire repair cycle of DNA replication has been identified for the first time...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 October 2020 • 2 minutes read

Precision cancer drug targets DNA repair

by Dr Melania Montes Pérez

A new anti-tumour drug that prevents cancer cells from repairing their DNA shows promising results in an early-stage clinical trial...

Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
CC BY-SA 3.0
Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
News
15 May 2020 • 2 minutes read

First epigenetic study in 3D human cancer cells

by Dr Charlott Repschläger

Researchers have, for the first time, characterised the epigenetic profile of tumour organoids and made their results available in public databases...

Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
CC BY-SA 3.0
Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
News
7 February 2020 • 2 minutes read

Global cancer genome study reveals genetic secrets

by Isobel Steer

The largest-ever study of cancer genomes, the Pan-Cancer Project, has published a collection of 23 papers as the result of a ten-year collaboration...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
6 December 2019 • 2 minutes read

Junk DNA may affect cancer risk

Scientists have found that genetic variation in regions of DNA that do not code for proteins, previously characterised as 'junk DNA', may affect a person's risk to develop a form of inherited cancer...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Polycystic ovary syndrome may have more than two different subtypes

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856